ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, dasatinib, a dual-specific TKI targeting both BCR-ABL and the Src family kinases (e.g., Lyn) (26) is active against both imatinib-sensitive and -resistant CML via target-dependent or -independent mechanisms (99).